FRA:RHO - Deutsche Boerse Ag - CH0012032113 - Common Stock - Currency: EUR
Taking everything into account, RHO scores 6 out of 10 in our fundamental rating. RHO was compared to 53 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making RHO a very profitable company, without any liquidiy or solvency issues. RHO has a valuation in line with the averages, but it does not seem to be growing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 8.13% | ||
ROE | 26.06% | ||
ROIC | 22.12% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 33.2% | ||
PM (TTM) | 13.68% | ||
GM | 73.91% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.98 | ||
Debt/FCF | 2.3 | ||
Altman-Z | 3.99 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.48 | ||
Quick Ratio | 1.2 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 15.24 | ||
Fwd PE | 13.76 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 15.37 | ||
EV/EBITDA | 10.14 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 3.56% |
FRA:RHO (6/13/2025, 7:00:00 PM)
306.2
-2.2 (-0.71%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 3.56% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 15.24 | ||
Fwd PE | 13.76 | ||
P/S | 3.83 | ||
P/FCF | 15.37 | ||
P/OCF | 11.54 | ||
P/B | 7.3 | ||
P/tB | 35.2 | ||
EV/EBITDA | 10.14 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 8.13% | ||
ROE | 26.06% | ||
ROCE | 26.86% | ||
ROIC | 22.12% | ||
ROICexc | 28.73% | ||
ROICexgc | 50.83% | ||
OM | 33.2% | ||
PM (TTM) | 13.68% | ||
GM | 73.91% | ||
FCFM | 24.94% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.98 | ||
Debt/FCF | 2.3 | ||
Debt/EBITDA | 1.33 | ||
Cap/Depr | 146.33% | ||
Cap/Sales | 8.28% | ||
Interest Coverage | 17.54 | ||
Cash Conversion | 85.47% | ||
Profit Quality | 182.25% | ||
Current Ratio | 1.48 | ||
Quick Ratio | 1.2 | ||
Altman-Z | 3.99 |